-
1
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
Pryer, N.K.4
Cherrington, J.M.5
-
2
-
-
33749544080
-
An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
-
Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC et al (2006) An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076
-
(2006)
J. Clin. Endocrinol. Metab.
, vol.91
, pp. 4070-4076
-
-
Kim, D.W.1
Jo, Y.S.2
Jung, H.S.3
Chung, H.K.4
Song, J.H.5
Park, K.C.6
-
3
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
-
4
-
-
9144274970
-
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766
-
(2003)
Clin. Exp. Metastasis
, vol.20
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
Ngai, T.J.4
Olson, L.M.5
Hong, W.6
-
5
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
O'Farrell, A.M.1
Abrams, T.J.2
Yuen, H.A.3
Ngai, T.J.4
Louie, S.G.5
Yee, K.W.6
-
6
-
-
18144368022
-
-
SUTENT sunitinib malate, Pfizer, New York
-
SUTENT (sunitinib malate) prescribing information (2007) Pfizer, New York
-
(2007)
Prescribing Information
-
-
-
7
-
-
49149114782
-
Activity of sunitinib in patients with advanced neuroendocrine tumors
-
Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 3403-3410
-
-
Kulke, M.H.1
Lenz, H.J.2
Meropol, N.J.3
Posey, J.4
Ryan, D.P.5
Picus, J.6
-
8
-
-
42949148257
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 1810-1816
-
-
Burstein, H.J.1
Elias, A.D.2
Rugo, H.S.3
Cobleigh, M.A.4
Wolff, A.C.5
Eisenberg, P.D.6
-
9
-
-
70350655546
-
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced nonsmall cell lung cancer
-
in press
-
Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer JR, Atkins JN et al. (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced nonsmall cell lung cancer. Br J Cancer (in press)
-
(2009)
Br. J. Cancer
-
-
Novello, S.1
Scagliotti, G.V.2
Rosell, R.3
Socinski, M.A.4
Brahmer, J.R.5
Atkins, J.N.6
-
10
-
-
39149120621
-
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
-
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 650-656
-
-
Socinski, M.A.1
Novello, S.2
Brahmer, J.R.3
Rosell, R.4
Sanchez, J.M.5
Belani, C.P.6
-
11
-
-
33646108821
-
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects
-
Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J et al (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358
-
(2006)
Anticancer Drugs
, vol.17
, pp. 353-358
-
-
Bello, C.L.1
Sherman, L.2
Zhou, J.3
Verkh, L.4
Smeraglia, J.5
Mount, J.6
-
12
-
-
65249140620
-
A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib in healthy male subjects
-
Poster presentation at, April 14-18, 2007 Los Angeles, CA, USA Abstract 9072
-
Bello CL, Bu HZ, Patyna S, Kang P, Peng G, Pool W et al. (2007) A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib in healthy male subjects. Poster presentation at the AACR annual meeting, April 14-18, 2007 (Los Angeles, CA, USA) (Abstract 9072)
-
(2007)
The AACR Annual Meeting
-
-
Bello, C.L.1
Bu, H.Z.2
Patyna, S.3
Kang, P.4
Peng, G.5
Pool, W.6
-
13
-
-
68149137164
-
Single-and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species
-
Haznedar JÖ, Patyna S, Bello CL, Peng GW, Speed W, Yu X et al (2009) Single-and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Can Chemother Pharmacol 64:691-706
-
(2009)
Can. Chemother. Pharmacol.
, vol.64
, pp. 691-706
-
-
Haznedar, J.Ö.1
Patyna, S.2
Bello, C.L.3
Peng, G.W.4
Speed, W.5
Yu, X.6
-
14
-
-
65249087328
-
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
-
Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Can Res 15:2497-2506
-
(2009)
Clin. Can. Res.
, vol.15
, pp. 2497-2506
-
-
Houk, B.E.1
Bello, C.L.2
Kang, D.3
Amantea, M.4
-
15
-
-
0013771649
-
Surgery and portal hypertension
-
Child CG ed, WB Saunders, Philadelphia
-
Child CG, Turcotte JG (1964) Surgery and portal hypertension. In: Child CG (ed) The liver in portal hypertension. WB Saunders, Philadelphia, pp 1-85
-
(1964)
The Liver in Portal Hypertension
, pp. 1-85
-
-
Child, C.G.1
Turcotte, J.G.2
-
16
-
-
0015854966
-
Transection of the oesophagus for bleeding oesophageal varices
-
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649
-
(1973)
Br. J. Surg.
, vol.60
, pp. 646-649
-
-
Pugh, R.N.1
Murray-Lyon, I.M.2
Dawson, J.L.3
Pietroni, M.C.4
Williams, R.5
-
17
-
-
72549097409
-
A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
-
Abstract 2911
-
Rosen LS, Bello CL, Mulay M, Dinolfo M, Baum C (2006) A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors. Proc Am Assoc Cancer Res 47 (Abstract 2911)
-
(2006)
Proc. Am. Assoc. Cancer Res.
, vol.47
-
-
Rosen, L.S.1
Bello, C.L.2
Mulay, M.3
Dinolfo, M.4
Baum, C.5
-
18
-
-
78149361846
-
Pharmacokinetics in patients with impaired hepatic function: Study design
-
FDA Guidance for Industry, May 2003
-
FDA Guidance for Industry (2003) Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. May 2003
-
(2003)
Data Analysis, and Impact on Dosing and Labeling
-
-
-
19
-
-
77954843443
-
Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function
-
Sept 24th Epub Ahead of Print
-
Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury T et al. (2009) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol (Sept 24th Epub Ahead of Print)
-
(2009)
J. Clin. Pharmacol.
-
-
Khosravan, R.1
Toh, M.2
Garrett, M.3
La Fargue, J.4
Ni, G.5
Marbury, T.6
-
20
-
-
33644843464
-
Pathophysiology of water and sodium retention: Edematous states with normal kidney function
-
Bekheirnia M, Shrier R (2007) Pathophysiology of water and sodium retention: edematous states with normal kidney function. Curr Opin Pharmacol 6:202-207
-
(2007)
Curr. Opin. Pharmacol.
, vol.6
, pp. 202-207
-
-
Bekheirnia, M.1
Shrier, R.2
-
21
-
-
0344308514
-
Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites
-
Cárdenas A, Arroyo V (2003) Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 17:607-622
-
(2003)
Best Pract. Res. Clin. Endocrinol. Metab.
, vol.17
, pp. 607-622
-
-
Cárdenas, A.1
Arroyo, V.2
-
23
-
-
67651165187
-
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: A phase II study
-
Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: a phase II study. Lancet Oncol 10:794-800
-
(2009)
Lancet Oncol.
, vol.10
, pp. 794-800
-
-
Faivre, S.1
Raymond, E.2
Boucher, E.3
Douillard, J.4
Lim, H.Y.5
Kim, J.S.6
-
24
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
Robert, C.4
Lozahic, S.5
Lassau, N.6
-
25
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Jaap V et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
-
(2006)
Lancet
, vol.368
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
Blackstein, M.E.4
Shah, M.H.5
Jaap, V.6
|